

Peter M George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7811136/publications.pdf>

Version: 2024-02-01

34
papers

2,270
citations

471509

17
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

4003
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. <i>Lancet Respiratory Medicine</i> , 2020, 8, 807-815.	10.7	802
2	Respiratory follow-up of patients with COVID-19 pneumonia. <i>Thorax</i> , 2020, 75, 1009-1016.	5.6	266
3	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. <i>Lancet Respiratory Medicine</i> , 2020, 8, 925-934.	10.7	198
4	Lung transplantation for idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 271-282.	10.7	168
5	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 759-770.	10.7	145
6	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143
7	Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. <i>Circulation Research</i> , 2014, 114, 677-688.	4.5	124
8	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 339-347.	5.6	45
9	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. <i>Respirology</i> , 2018, 23, 687-694.	2.3	39
10	King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. <i>European Respiratory Journal</i> , 2019, 54, 1900281.	6.7	37
11	Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 486-491.	2.1	33
12	Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy. <i>Pulmonary Circulation</i> , 2017, 7, 643-653.	1.7	33
13	The potential impact of azithromycin in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1800628.	6.7	32
14	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 483-491.	3.1	31
15	Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. <i>Respirology</i> , 2021, 26, 461-468.	2.3	30
16	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001049.	3.0	28
17	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality. <i>European Respiratory Journal</i> , 2019, 53, 1802412.	6.7	20
18	Endothelin-1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. <i>Pulmonary Circulation</i> , 2012, 2, 501-504.	1.7	19

#	ARTICLE	IF	CITATIONS
19	A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. <i>ERJ Open Research</i> , 2018, 4, 00124-2017.	2.6	16
20	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1901681.	6.7	11
21	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 317, L431-L433.	2.9	9
22	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 127-135.	3.0	8
23	Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans. <i>ERJ Open Research</i> , 2020, 6, 00290-2019.	2.6	8
24	Hiatus hernia and interstitial lung abnormalities. <i>European Respiratory Journal</i> , 2020, 56, 2001679.	6.7	6
25	Hypoxic Challenge Testing for Fitness to Fly with Severe Asthma. <i>Aerospace Medicine and Human Performance</i> , 2016, 87, 571-574.	0.4	5
26	COVID-19 pneumonia and the pulmonary vasculature: a marriage made in hell. <i>European Respiratory Journal</i> , 2021, 58, 2100811.	6.7	4
27	An emerging interstitial lung disease. <i>Lancet Respiratory Medicine</i> , 2016, 4, 762.	10.7	2
28	Rapidly Progressive Cystic Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 264-264.	5.6	2
29	Restrictive lung defects: parenchymal, chest wall and neuromuscular. <i>Thorax</i> , 2018, 73, 989-991.	5.6	2
30	Contemporary Concise Review 2019: Interstitial lung disease. <i>Respirology</i> , 2020, 25, 756-763.	2.3	2
31	Dissecting the role of the small airways in idiopathic pulmonary fibrosis. <i>Lancet Respiratory Medicine</i> , 2020, 8, 529-531.	10.7	2
32	Use of interferon beta for acute respiratory distress syndrome: proceed with caution. <i>Lancet Respiratory Medicine</i> , 2014, 2, e2.	10.7	0
33	Letter by Reed et al Regarding Article, "Proteomic Analysis Implicates Translationally Controlled Tumor Protein as a Novel Mediator of Occlusive Vascular Remodeling in Pulmonary Arterial Hypertension". <i>Circulation</i> , 2015, 131, e347.	1.6	0
34	Reply to Althwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 522-524.	5.6	0